Amryt Pharma Holdings Ltd (AMYT) Stock
AMYT is no longer traded. Amryt Pharma Holdings was delisted from the Nasdaq in April 2023.
Prices on this page are historical; the last trade was April 11, 2023 at $14.70.
Amryt Pharma Holdings stock price history
AMYT final trading statistics
- Final close
- $14.70
- Final trading day
- Apr 11, 2023
- Market cap at delisting
- $942.77M
- Shares outstanding
- 64.13M
- Final 52-week range
- $6.41 – $14.77
- Avg. volume (final 3 mo.)
- 539,985
- All-time high (split-adj.)
- $14.77 · Jan 2023
- All-time low (split-adj.)
- $6.30 · Mar 2022
- Return since IPO
- +30.7%
- Beta
- 0.77
- Book value / share
- $5.07
- Price / book
- 2.90
Amryt Pharma Holdings annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $222.54M | -$18.2M | $0.63 |
| FY2020 | $182.61M | -$104.5M | -$2.45 |
| FY2019 | $58.12M | -$65.5M | — |
| FY2018 | $16.53M | -$29.5M | — |
| FY2017 | $15.33M | -$31.4M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Amryt Pharma Holdings Ltd
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
Amryt Pharma Holdings stock FAQ
What happened to Amryt Pharma Holdings stock?
Amryt Pharma Holdings stock was delisted from the Nasdaq. Its final close was $14.70 on April 11, 2023.
Is AMYT stock still trading?
No. AMYT was delisted from the Nasdaq in April 2023 and no longer trades on a U.S. exchange.
What was the last price of AMYT stock?
AMYT closed at $14.70 on its final trading day, April 11, 2023, for a market value of about $942.77M.
What were Amryt Pharma Holdings's revenue and earnings in its last full fiscal year?
Amryt Pharma Holdings reported revenue of $222.54M and net income of -$18.2M in fiscal 2021, its last full year as a public company.
When did Amryt Pharma Holdings go public?
Amryt Pharma Holdings Ltd stock began trading on December 31, 2019.